The US Food and Drug Administration on Friday approved Baxter International’s (NYSE: BAX) and Halozyme Therapeutics’ (Nasdaq: HALO) subcutaneous treatment for adult patients with primary immunodeficiency (PI), HyQvia (immune globulin infusion 10% [human] with recombinant human hyaluronidase).
HyQvia is the first subcutaneous immune globulin (IG) treatment approved for PI patients with a dosing regimen requiring only one infusion up to once per month (every three to four weeks) and one injection site per infusion to deliver a full therapeutic dose of IG. The majority of PI patients today receive intravenous infusions in a doctor’s office or infusion center, and current subcutaneous IG treatments require weekly or bi-weekly treatment with multiple infusion sites per treatment.
''Patients with PI value treatments that offer efficacy, safety and tolerability. Since each person with PI responds differently to treatment, having options that meet these individual needs is critically important,'' commented Marcia Boyle, president and founder of the Immune Deficiency Foundation, adding: ''We commend Baxter for its significant commitment and investment in the development of HyQvia.''
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze